Michael Frederick Bassetti

Michael Frederick Bassetti

Auto-generated profile, based on publicly available information

Michael Frederick Bassetti

University of Wisconsin Carbone Cancer Center 3 , Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
AWAndrzej P. Wojcieszynski
Andrzej P. Wojcieszynski
SRStephen A. Rosenberg
Stephen A. Rosenberg
JBJeffrey V. Brower
Jeffrey V. Brower
CHCraig R. Hullett
Craig R. Hullett
MGMark W. Geurts
Mark W. Geurts
MBMichael F. Bassetti
Michael F. Bassetti

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NUNataliya Volodymyrivna Uboha
Nataliya Volodymyrivna Uboha
JMJames D. Maloney
James D. Maloney
DMDaniel McCarthy
Daniel McCarthy
DDDustin Deming
Dustin Deming
NLNoelle K. LoConte
Noelle K. LoConte
MBMichael Frederick Bassetti
Michael Frederick Bassetti
4041 Background: Neoadjuvant CRT followed by surgery is the standard of care (SOC) for patients (pts) with stage II/III E/GEJ cancer. However, recurrence rates are high. Immunotherapy has demonstrated promising activity in advanced E/GEJ cancer. This trial evaluates safety and efficacy of perioperative A with CRT in resectable E/GEJ cancer. Methods: This is a 2-part phase I/II trial. Part 1 is a run-in phase with 6 pts for safety evaluation. Part 2 will enroll additional 18 pts in the expansion cohort. Pts with E/GEJ cancer of any histology receive CRT (41.4 Gy in 23 fractions) with carboplatin and paclitaxel as per SOC. Three doses of A (10 mg/kg, q14 days) are administered starting on day 29 of treatment, to coincide with the last chemotherapy dose. Surgery is performed ~8 weeks after CRT completion. Pts receive 6 doses of A after resection. Dose-limiting toxicity (DLT) evaluations are completed on the first post-operative clinic visit, 2-4 weeks post resection. Results: Between 6/2018 and 2/2019, 6 pts (all male, median age 62) enrolled in part 1: 6 adenocarcinoma (100%); 1 E, 3 Siewert 1, 2 Siewert 2; 1 cT2N0, 2 cT3N0, 3 cT3N1. All pts underwent successful resection with negative surgical margins. 1/6 pts had R1 resection due to tumor extension to inked adventitial surface without invasion of surrounding structures. There were no unexpected surgical complications. At resection, 2 pts had ypT0N0, 2 ypT1N0, 1 ypT2N0, and 1 ypT3N1 disease. Combination of CRT and A had an acceptable toxicity profile. No DLTs were seen in the first 5 pts, so expansion cohort is open to enrollment. No grade ≥3 immune-related AEs were observed. Immune-related hypothyroidism was seen in 1 patient (grade 2). 6/6 pts had reversible grade 3 or 4 lymphopenia; 1/6 had grade 3 neutropenia. Correlative studies are ongoing and will be presented at the meeting. Conclusions: Perioperative CRT with A is well tolerated with no unexpected toxicities. Additional safety and correlative data will be presented at the meeting. This study is actively enrolling pts to an expansion cohort at University of Wisconsin. Clinical trial information: NCT03490292.

1 November 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ACA.M.A. De Costa
A.M.A. De Costa
KMK.E. Mittauer
K.E. Mittauer
PHPatrick Hill
Patrick Hill
MBM.F. Bassetti
M.F. Bassetti
JBJ. Bayouth
J. Bayouth
ABAndrew M. Baschnagel
Andrew M. Baschnagel

24 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
DDDustin Deming
Dustin Deming
SKSean G. Kraus
Sean G. Kraus
JBJoshua Brand
Joshua Brand
KJKatherine Johnson
Katherine Johnson
DADaniel Abbott
Daniel Abbott
MBMichael F. Bassetti
Michael F. Bassetti
Purpose: Versican (VCAN) is an immunoregulatory matrix proteoglycan that, when cleaved, releases an immunostimulatory fragment, versikine. In this study, we evaluate the impact of VCAN on immune surveillance and immunotherapy response in a prospective clinical trial. Patients and Methods: T-cell function was assayed in the setting of VCAN. Normal and matched tissues were acquired from 243 patients across colorectal cancer stages. A phase Ib clinical trial enrolled 15 subjects with microsatellite stable oligometastatic colorectal cancer and examined the safety and efficacy of the sequential combination of stereotactic body radiotherapy, pembrolizumab, and resection (NCT02837263). The outcomes were correlated with the VCAN status and circulating immune phenotype by single-cell RNA sequencing. Results: VCAN significantly accumulates in 59% of colorectal cancers and is heavily proteolyzed [VCAN proteolytic predominant (VPP)] in 27% (40% of oligometastatic colorectal cancers). VCAN decreased CD8+ T-cell trafficking (P < 0.01) and activated CD8+ T-cell effector function [decreased IL2RA (P < 0.05), PD-1 (P < 0.05), and granzyme B (GZMB; P < 0.001)]. The clinical trial met the primary endpoint with a 1-year recurrence-free survival (RFS) of 60%. Of those enrolled, 40% had the VPP phenotype, which was associated with a trend toward improved RFS (P = 0.053), and all are still alive with a median follow-up of 4.1 years. The VPP phenotype was associated with enhanced circulating CD8+ T-cell effector function at baseline, which was further enhanced with study treatment. Conclusions: VCAN limits T-cell trafficking and effector function, and its proteolysis correlates with an effector phenotype of circulating CD8+ T cells, greater tumor-infiltrating lymphocytes, and improved clinical outcomes with this immunotherapy-based clinical trial treatment.

5 December 2025 in Science Advances
Verified
Journal Article
Open access
MRMD MAHFUZUR RAHMAN
MD MAHFUZUR RAHMAN
APAndrea Pennati
Andrea Pennati
TATavus Atajanova
Tavus Atajanova
TDTrishna Debnath
Trishna Debnath
RARaad H. Allawi
Raad H. Allawi
ZMZachary S. Morris
Zachary S. Morris
Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell–enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP IL2ZA ) with low-dose radiotherapy (RT) and monoclonal antibodies (mAbs) to overcome this immunosuppressive TME. ICP IL2ZA is composed of natural killer (NK) cell– and monocyte-enriched immune cells, activated ex vivo with IL-2 and ZA. ICP IL2ZA with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosis against PDAC. In murine models of PDAC, RT and mAb combined with ICP IL2ZA derived from either murine or healthy human donors controlled tumor growth. RT amplifies ICP IL2ZA effectiveness by inducing NKG2D ligands on tumor cells, facilitating immune infiltration that leads to tumor growth control and extends survival without apparent toxicity. These results suggest that ICP IL2ZA can overcome limitations of traditional therapies by augmenting antitumor capabilities of endogenous immune cells, highlighting a promising autologous strategy for PDAC and other immunologically “cold” tumors.

1 January 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
MTMichael J. Thomas
Michael J. Thomas
HBHeather L. Bartlett
Heather L. Bartlett
MBMichael F. Bassetti
Michael F. Bassetti
SLSam J. Lubner
Sam J. Lubner
GKGeorgios Kirvassilis
Georgios Kirvassilis
RMRyan A. Macke
Ryan A. Macke
Improvements in surgical technique and perioperative care have resulted in increased long-term survival for patients with congenital heart disease. As these patients begin to reach their later years, clinicians are challenged with determining optimal management of noncardiac diseases in this complex patient population, including surgically treatable malignancies. We present a case of esophageal cancer in a patient with previously repaired tetralogy of Fallot and right-sided aortic arch, treated with neoadjuvant therapy followed by laparoscopic and left thoracoscopic esophagectomy.